EMA advises to approve Nordic Bavarian monkeypox vaccine

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has met to analyze various medicines. One of them was the smallpox vaccine from the Nordic Bavarian pharmaceutical company. They recommend that Europe approves Imvanex as treatment for monkeypox.

Imvanex was approved in Europe in 2013 for smallpox vaccination in adults over 18 years of age. Now the committee is advising that Europe admit the vaccine as a treatment for monkeypox in a time when infections are rising in some countries. In the United States and Canada, the authorization of Imvanex has been extended to include the virus among the indications.

In May, when monkeypox cases emerged in Spain, Health Minister Carolina Darias announced that Europe would buy antivirals for this disease from the Danish pharmaceutical company through a centralized purchase in which Spain participated. “We have already supplied our vaccine to many European countries during the current outbreak, including supplies for the European Union common stock facilitated by the European Health Emergency Preparedness and Response Authority (HERA),” indicates the report. Paul Chaplin. “The label extension will help improve access to the vaccine across Europe and strengthen future preparedness against monkeypox.”

In addition to recommending its use for the prevention of monkeypox, he also advises to authorize the antiviral against disease caused by vaccinia virus. It causes milder symptoms than those of smallpox. In the next few days, the committee’s recommendations will be sent to the European Commission, which will decide whether to approve it or not.

Other medications you recommend

The Committee for Medicinal Products for Human Use (CHMP) recommended that Europe approve a total of 11 drugs. Among medications, the committee advises giving the green light to Otsuka’s pharmaceutical treatment for lupus nephritis, an inflammation of the kidney caused by lupus. It also recommends giving Bristol Myers Squibb’s drug Opdualag the green light. It’s a therapy for melanoma. On the other hand, the CHMP issued a positive opinion on Roche’s treatment, Vabysmo, for the treatment of wet or neovascular age-related macular degeneration and for visual impairment due to diabetic macular oedema.


Leave a Comment